Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BCL-2 family protein expression and platinum drug resistance in ovarian carcinoma

1 Jan 2000

Abstract excerpt

The expression of the BCL-2 family proteins, BCL-2, BAX, BCL(XL) and BAK have been determined in a panel of 12 human ovarian carcinoma cell lines encompassing a wide range in sensitivity to cisplatin. Whereas BAX, BCL(XL) and BAK levels did not correlate with sensitivity, there was a statistically significant inverse correlation (r = -0.81; P = 0.002) between growth inhibition by cisplatin and BCL-2 levels. In...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell death mechanisms and regulation
Share to Chronic Myeloid Leukemia Treatments
Share to RNA Interference and Gene Delivery

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 10646901
DOI: 10.1054/bjoc.1999.0939

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BCL-2 family protein expression and platinum drug resistance in ovarian carcinomaPMID 10646901Read ↗

Bcl‑2 family: Novel insight into individualized therapy for ovarian cancer (Review)Semantic proximity Read ↗

Bcl-2 overexpression results in reciprocal downregulation of Bcl-XL and sensitizes human testicular germ cell tumours to chemotherapy-induced apoptosisSemantic proximity Read ↗

Increased bcl-2 expression is associated with primary resistance to chemotherapy in human epithelial ovarian cancer.Semantic proximity Read ↗

Metallothionein gene expression and resistance to cisplatin in human ovarian cancerSemantic proximity Read ↗

REGULATION OF CLINICAL CHEMORESISTANCE BY bcl‐2 AND BAX ONCOPROTEINS IN B‐CELL CHRONIC LYMPHOCYTIC LEUKAEMIASemantic proximity Read ↗

Development of resistance to a trinuclear platinum complex in ovarian carcinoma cellsSemantic proximity Read ↗

Altered ErbB Receptor Signaling and Gene Expression in Cisplatin-Resistant Ovarian CancerSemantic proximity Read ↗

Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-BSemantic proximity Read ↗

Enhancing cisplatin sensitivity in MCF-7 human breast cancer cells by down-regulation of Bcl-2 and cyclin D1Semantic proximity Read ↗

The bcl-2 gene status of human head and neck cancer cell lines.Semantic proximity Read ↗

Chemoresistance to paclitaxel in human ovarian xenografts : the role of apoptosis-regulating proteinsSemantic proximity Read ↗

Downregulation of AKT reverses platinum resistance of human ovarian cancers in vitroSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.